Imiquimod in cervical, vaginal and vulvar intraepithelial neoplasia: A review

Witte, Chris J. de; Sande, A. J. M. van de; Beekhuizen, Heleen J. van; Koeneman, Margot M.; Kruse, Arnold‐Jan; Gerestein, C.G.

doi:10.1016/j.ygyno.2015.08.018

Cited by 95 publications

(68 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The symptoms all disappeared after discontinuation of imiquimod. In a previous review, De Witte et al showed a higher rate of adverse effects in imiquimod use compared with placebo; however, these adverse effects were less severe than in our study [7]. The most common and severe local and systemic effects reported in literature are summarized in Table 2.…”

Section: Discussioncontrasting

confidence: 41%

Systemic adverse events in imiquimod use for cervical intraepithelial neoplasia – A case series

Wouters

Hendriks

Koeneman

et al. 2019

Case Reports in Women's Health

View full text Add to dashboard Cite

Treatment for cervical intraepithelial neoplasia (CIN) often consists of an excisional procedure. However, less invasive treatment methods have been explored, such as topical treatment with imiquimod cream. Imiquimod has been proven to be effective in the regression of vulvar intraepithelial neoplasia (VIN) and vaginal intraepithelial neoplasia (VAIN). Previous studies have investigated the effect of imiquimod in CIN and showed well tolerated adverse effects. During a current study in the Netherlands, a number of adverse events have occurred. This case series presents a selection of these. Gynaecologists should be aware of the possible adverse effects of topical treatment with imiquimod cream.

show abstract

Section: Discussioncontrasting

confidence: 41%

Systemic adverse events in imiquimod use for cervical intraepithelial neoplasia – A case series

Wouters

Hendriks

Koeneman

et al. 2019

Case Reports in Women's Health

View full text Add to dashboard Cite

show abstract

“…As synthetic small molecules, imidazoquinolines can be manufactured cost effectively and at high purity. The TLR7 ligand imiquimod is the active component in the topical cream Aldara ® , approved for human immunotherapeutic use to treat skin cancer and genital warts48. However, use of injected imidazoquinolines as vaccine adjuvants have not progressed beyond clinical testing.…”

mentioning

confidence: 99%

A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines

Hoeven

Fox

Granger

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Since 1997, highly pathogenic avian influenza viruses of the H5N1 subtype have been transmitted from avian hosts to humans. The severity of H5N1 infection in humans, as well as the sporadic nature of H5N1 outbreaks, both geographically and temporally, make generation of an effective vaccine a global public health priority. An effective H5N1 vaccine must ultimately provide protection against viruses from diverse clades. Toll-like receptor (TLR) agonist adjuvant formulations have a demonstrated ability to broaden H5N1 vaccine responses in pre-clinical models. However, many of these agonist molecules have proven difficult to develop clinically. Here, we describe comprehensive adjuvant formulation development of the imidazoquinoline TLR-7/8 agonist 3M-052, in combination with H5N1 hemagglutinin (HA) based antigens. We find that 3M-052 in multiple formulations protects both mice and ferrets from lethal H5N1 homologous virus challenge. Furthermore, we conclusively demonstrate the ability of 3M-052 adjuvant formulations to broaden responses to H5N1 HA based antigens, and show that this broadening is functional using a heterologous lethal virus challenge in ferrets. Given the extensive clinical use of imidazoquinoline TLR agonists for other indications, these studies identify multiple adjuvant formulations which may be rapidly advanced into clinical trials in an H5N1 vaccine.

show abstract

“…Conversely, 5% imiquimod cream promotes antitumoral activity via adaptive immune system activation. Success rates for various lesions have been reported to range from 76.3% to 88.0% 6, 7, 8. However, the safety of long‐term imiquimod use during pregnancy is unknown.…”

Section: Discussionmentioning

confidence: 99%

Vulvar intraepithelial neoplasia treated with a combination of surgical excision and laser ablation during pregnancy

Wang

Kawabe²,

Kikugawa³

et al. 2018

Clinical Case Reports

View full text Add to dashboard Cite

show abstract

Imiquimod in cervical, vaginal and vulvar intraepithelial neoplasia: A review

Abstract: Background and Aims:

Cited by 95 publications

References 44 publications

Systemic adverse events in imiquimod use for cervical intraepithelial neoplasia – A case series

Systemic adverse events in imiquimod use for cervical intraepithelial neoplasia – A case series

A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines

Vulvar intraepithelial neoplasia treated with a combination of surgical excision and laser ablation during pregnancy

Contact Info

Product

Resources

About